Biogen Inc
XHAM:IDP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Biogen Inc
XHAM:IDP
|
US |
Revenue Breakdown
Breakdown by Geography
Biogen Inc
Breakdown by Segments
Biogen Inc
|
Total Revenue:
9.9B
USD
|
|
Reportable Segment:
9.7B
USD
|
|
Product Revenue, Net:
7.2B
USD
|
|
Subtotal: Multiple Sclerosis:
4.3B
USD
|
|
Subtotal: Rare Disease:
2B
USD
|
|
Revenue From Anti-Cd20 Therapeutic Programs:
1.7B
USD
|
|
Total Fumarate:
1.6B
USD
|
|
Spinraza:
1.6B
USD
|
|
Royalty Revenue On Sales Of Ocrevus:
1.3B
USD
|
|
Total Interferon:
968m
USD
|
|
Subtotal: Biosimilars:
793.1m
USD
|
|
Contract Manufacturing, Royalty And Other Rev...:
652.6m
USD
|
|
Vumerity:
628m
USD
|
|
Contract Manufacturing Revenue:
592.1m
USD
|
|
Other:
82.5m
USD
|
|
Royalty And Other Revenue:
60.5m
USD
|
|
Alzheimer's Collaboration Revenue:
59.9m
USD
|
|
Qalsody:
32.4m
USD
|